MarketPulse

T-cell therapy

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Anaveon Ag

Biotech Veteran Ramanayake Takes Helm at Anaveon as Immune Reprogramming Firm Pursues Clinical Trials

Anaveon appoints veteran biotech executive Thaminda Ramanayake as CEO to guide lead candidate ANV200 through clinical development for autoimmune and inflammatory diseases.
PFENVSBNTXclinical developmentautoimmune diseases
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Tevogen Bio Advances Long COVID Therapy With Expanded HLA Coverage and Digital Care Platform

Tevogen Bio ($TVGN) expands T-cell therapy coverage to 65% of U.S. population and pursues digital care platform acquisition to advance Long COVID treatment.
TVGNTVGNWclinical trialprecision medicine